Back HIV/AIDS

HIV / AIDS

IAS 2015: Implant and Injectable Hormonal Contraception Most Effective Methods for Women with HIV

Hormonal contraceptive methods are highly effective in reducing the risk of pregnancy in women living with HIV whether on antiretroviral therapy (ART) or not, according to an evaluation involving over 5000 women, according to a report at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver last month.

alt

IAS 2015: A Community Perspective on HIV Prevention Science [VIDEO]

Dazon Dixon Diallo from SisterLove, Inc. in Atlanta and the U.S. Women and PrEP Working Group offered a community perspective at a press briefing on early antiretroviral therapy (ART), treatment as prevention, and pre-exposure prophylaxis (PrEP) research at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last month in Vancouver.

alt

IAS 2015: START Supports ART For All [VIDEO]

Full results from the Strategic Timing of Antiretroviral Treatment (START) trial provide definitive evidence that starting antiretroviral therapy (ART) soon after HIV diagnosis, rather than waiting until the CD4 T-cell count falls below 500 cells/mm3, significantly reduces the risk of AIDS-related and non-AIDS illness and death, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.

alt

IAS 2015: Altered Cholesterol Metabolism May Protect Immune Cells of Non-Progressors

Enhanced cholesterol metabolism in certain immune cells may help explain why some people with HIV can naturally control the virus with little or no disease progression, according to research presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention and at the preceding IAS Towards an HIV Cure Symposium last month in Vancouver. The findings suggest that regulating cellular cholesterol metabolism may offer a new approach to controlling HIV and potentially achieving a functional cure, or long-term remission.

alt

IAS 2015: WAVES Shows Elvitegravir Regimen Beats Boosted Atazanavir for Women with HIV

A study of antiretroviral treatment specifically for women with HIV showed that a single-tablet regimen containing the integrase inhibitor elvitegravir suppressed the virus better than a regimen containing ritonavir-boosted atazanavir, according to a poster presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver. This study is important in part because it demonstrates that including more women in clinical trials is feasible.

alt

IAS 2015: Indiana HIV Outbreak -- Lessons about Containing Local Outbreaks and Harm Reduction

An early 2015 outbreak of HIV and hepatitis C virus (HCV) infection in rural Indiana linked to injection of prescription opiates offers a good example to how to track and contain a localized outbreak, according to a pair of presentations at a late-breaking prevention research session at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last month in Vancouver. Attendees at the session stressed that we already know how to prevent such outbreaks, and called for implementation of needle exchange programs and other proven-effective harm reduction measures.

alt

IAS 2015: Pros and Cons of PrEP -- Volunteers Recount their Experiences in ADAPT Study

The reasons people come forward for pre-exposure prophylaxis (PrEP) or take it once prescribed are likely to be very mixed, and dependent as much on local political and cultural beliefs as they are on more personal factors like relationship status, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) last month in Vancouver.

alt